# US 11,332,441 B2 · Crystalline N-methyl tryptamine derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,332,441 B2
- Document ID: US11332441B2
- Status: Granted
- Kind: B2
- Application number: 16/827,072
- Filed: 2020-03-23
- Published: 2021-09-30
- Granted: 2022-05-17
- Earliest claimed: 2020-03-23
- Assignees: Caamtech, Inc.
- Applicants: Caamtech LLC
- Inventors: Andrew R. Chadeayne
- Web page: https://patentgrep.com/patent/US11332441B2

## CPC

- C07D 209/16: Tryptamines
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Crystalline N-methyl tryptamine derivatives, compositions containing those crystalline forms and their methods of use are disclosed. The crystalline N-methyl tryptamine derivatives according to the invention include crystalline N-methyl-N-propyltryptamine (MPT), crystalline N-methyl-N-isopropyltryptammonium fumarate (MiPT fumarate) and crystalline 4-hydroxy-N-methyl-N-isopropyltryptammonium fumarate monohydrate (HO-MiPT fumarate monohydrate).

## Claims

### Claim 1

Crystalline N-methyl-N-propyltryptamine (MPT) characterized by one or more of:
an orthorhombic, Pbca crystal system space group at a temperature of about 200 K;
unit cell dimensions a=13.5715 (11) Å, b=12.4352(10) Å, c=15.1627(12) Å, at a temperature of about 200 K;
or
an x-ray powder diffraction (XRPD) pattern having peaks at 11.7, 13.4 and 19.4° 2θ±0.2° 2θ.

### Claim 2 (depends on 1)

Crystalline N-methyl-N-propyltryptamine (MPT) according to claim 1, further characterized by an x-ray powder diffraction (XRPD) pattern substantially similar to FIG. 3.

### Claim 3 (depends on 1)

A composition comprising crystalline N-methyl-N-propyltryptamine (MPT) according to claim 1 and an excipient.

### Claim 4 (depends on 1)

A method of treating a psychological disorder comprising the step of:
administering to a subject in need thereof a therapeutically effective amount of crystalline N-methyl-N-propyltryptamine (MPT) according to claim 1.

### Claim 5 (depends on 2)

A method of treating a psychological disorder comprising the step of:
administering to a subject in need thereof a therapeutically effective amount of crystalline N-methyl-N-propyltryptamine (MPT) according to claim 2.

### Claim 6 (depends on 3)

A method of treating a psychological disorder comprising the step of:
administering to a subject in need thereof a composition according to claim 3.

### Claim 7

Crystalline N-methyl-N-isopropyltryptammonium fumarate (MiPT fumarate) characterized by one or more of:
a monoclinic, P21/c crystal system space group at a temperature of about 200 K;
unit cell dimensions a=9.852 (2) Å, b=12.789(2) Å, c=14.875 (3) Å, and β=106.932(7°) at a temperature of about 200 K;
or
an x-ray powder diffraction (XRPD) pattern having peaks at 11.9, 14.9 and 16.9° 2θ±0.2° 2θ.

### Claim 8 (depends on 7)

Crystalline N-methyl-N-isopropyltryptammonium fumarate (MiPT fumarate) according to claim 7, further characterized by an x-ray powder diffraction (XRPD) pattern substantially similar to FIG. 2.

### Claim 9 (depends on 7)

A composition comprising crystalline N-methyl-N-isopropyltryptammonium fumarate (MiPT fumarate) according to claim 7 and an excipient.

### Claim 10 (depends on 7)

A method of treating a psychological disorder comprising the step of:
administering to a subject in need thereof a therapeutically effective amount of crystalline N-methyl-N-isopropyltryptammonium fumarate (MiPT fumarate) according to claim 7.

### Claim 11 (depends on 8)

A method of treating a psychological disorder comprising the step of:
administering to a subject in need thereof a therapeutically effective amount of crystalline N-methyl-N-isopropyltryptammonium fumarate (MiPT fumarate) according to claim 8.

### Claim 12 (depends on 9)

A method of treating a psychological disorder comprising the step of:
administering to a subject in need thereof a composition according to claim 9.

### Claim 13

Crystalline 4-hydroxy-N-methyl-N-isopropyltryptammonium fumarate monohydrate (HO-MiPT fumarate monohydrate) characterized by one or more of:
a monoclinic, C2/c crystal system space group at a temperature of about 200 K;
unit cell dimensions a=29.507 (3) Å, b=8.7445(8) Å, c=17.3659 (18) Å, and β=123.389(18°) at a temperature of about 200 K;
or
an x-ray powder diffraction (XRPD) pattern having peaks at 7.2, 13.4 and 18.0° 2θ±0.2° 2θ.

### Claim 14 (depends on 13)

Crystalline 4-hydroxy-N-methyl-N-isopropyltryptammonium fumarate monohydrate (HO-MiPT fumarate monohydrate) according to claim 13, further characterized by an x-ray powder diffraction (XRPD) pattern substantially similar to FIG. 11.

### Claim 15 (depends on 13)

A composition comprising crystalline 4-hydroxy-N-methyl-N-isopropyltryptammonium fumarate monohydrate (HO-MiPT fumarate monohydrate) according to claim 13 and an excipient.

### Claim 16 (depends on 13)

A method of treating a psychological disorder comprising the step of:
administering to a subject in need thereof a therapeutically effective amount of crystalline 4-hydroxy-N-methyl-N-isopropyltryptammonium fumarate monohydrate (HO-MiPT fumarate monohydrate) according to claim 13.

### Claim 17 (depends on 14)

A method of treating a psychological disorder comprising the step of:
administering to a subject in need thereof a therapeutically effective amount of crystalline 4-hydroxy-N-methyl-N-isopropyltryptammonium fumarate monohydrate (HO-MiPT fumarate monohydrate) according to claim 14.

### Claim 18 (depends on 15)

A method of treating a psychological disorder comprising the step of:
administering to a subject in need thereof a composition according to claim 15.
